Cellectar Biosciences (CLRB) Short Interest Ratio & Short Volume $4.98 +0.20 (+4.18%) Closing price 09/4/2025 04:00 PM EasternExtended Trading$4.90 -0.08 (-1.69%) As of 05:18 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Cellectar Biosciences Short Interest DataCellectar Biosciences (CLRB) has a short interest of 94,400 shares, representing 3.19% of the float (the number of shares available for trading by the public). This marks a -34.49% decrease in short interest from the previous month. The short interest ratio (days to cover) is 0.2, indicating that it would take 0.2 days of the average trading volume of 151,293 shares to cover all short positions.Current Short Interest94,400 sharesPrevious Short Interest144,100 sharesChange Vs. Previous Month-34.49%Dollar Volume Sold Short$409.70 thousandShort Interest Ratio0.2 Days to CoverLast Record DateAugust 15, 2025Outstanding Shares3,190,000 sharesFloat Size2,960,000 sharesShort Percent of Float3.19%Today's Trading Volume79,870 sharesAverage Trading Volume151,293 sharesToday's Volume Vs. Average53% Short Selling Cellectar Biosciences? Sign up to receive the latest short interest report for Cellectar Biosciences and its competitors with MarketBeat's FREE newsletter. Email Address Get Report View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartCLRB Short Interest Over TimeCLRB Days to Cover Over TimeCLRB Percentage of Float Shorted Over Time Cellectar Biosciences Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 8/15/202594,400 shares $409.70 thousand -34.5%3.2%0.2 $4.34 7/31/2025144,100 shares $697.44 thousand +115.4%5.6%0.3 $4.84 7/15/202566,900 shares $319.78 thousand -59.5%2.6%0.2 $4.78 6/30/2025165,000 shares $1.17 million +140.2%6.4%0.4 $7.11 6/15/202568,700 shares $851.61 thousand -95.3%3.9%0.2 $12.40 5/31/20251,450,000 shares $363.95 thousand -39.3%3.2%0.1 $0.25 5/15/20252,390,000 shares $606.34 thousand +53.2%5.3%2.5 $0.25 4/30/20251,560,000 shares $392.50 thousand -31.0%3.4%1.5 $0.25 4/15/20252,260,000 shares $663.54 thousand +1.8%5.0%2 $0.29 3/31/20252,220,000 shares $699.97 thousand -24.0%4.9%1.4 $0.32 Get the Latest News and Ratings for CLRB and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Cellectar Biosciences and its competitors with MarketBeat's FREE daily newsletter. 3/15/20252,920,000 shares $921.55 thousand +48.2%6.4%1.5 $0.32 2/28/20251,970,000 shares $570.32 thousand -15.8%4.4%0.7 $0.29 2/15/20252,340,000 shares $680.47 thousand -0.9%5.2%0.9 $0.29 1/31/20252,360,000 shares $593.30 thousand -25.1%5.3%0.9 $0.25 1/15/20253,150,000 shares $781.52 thousand +67.6%7.9%1.3 $0.25 12/31/20241,880,000 shares $562.12 thousand -32.6%4.7%1 $0.30 12/15/20242,790,000 shares $725.40 thousand +114.6%7.0%1.8 $0.26 11/30/20241,300,000 shares $2.00 million +12.1%3.3%3.9 $1.54 11/15/20241,160,000 shares $2.16 million -37.0%2.9%3.6 $1.86 10/31/20241,840,000 shares $3.75 million -6.1%4.7%7.5 $2.04 10/15/20241,960,000 shares $4.00 million -10.9%5.7%6.2 $2.04 9/30/20242,200,000 shares $4.71 million +35.8%6.3%4.6 $2.14 9/15/20241,620,000 shares $3.45 million -37.0%4.7%3 $2.13 8/31/20242,570,000 shares $5.65 million +0.8%7.4%4.6 $2.20 8/15/20242,550,000 shares $5.18 million -10.2%7.4%4.3 $2.03 7/31/20242,840,000 shares $6.11 million +27.9%8.2%4.5 $2.15 7/15/20242,220,000 shares $5.68 million -2.2%6.4%3.4 $2.56 6/30/20242,270,000 shares $5.68 million -4.2%6.5%3.8 $2.50 6/15/20242,370,000 shares $7.63 million +9.2%6.8%3.5 $3.22 5/31/20242,170,000 shares $6.71 million -4.4%6.3%2.8 $3.09 5/15/20242,270,000 shares $7.63 million -11.0%6.5%2.4 $3.36 4/30/20242,550,000 shares $7.88 million +16.4%7.9%2.7 $3.09 4/15/20242,190,000 shares $7.27 million -13.4%7.5%2 $3.32 3/31/20242,530,000 shares $10.07 million +34.6%8.7%1.4 $3.98 3/15/20241,880,000 shares $6.54 million -6.5%16.9%1.1 $3.48 2/29/20242,010,000 shares $7.88 million -15.2%17.0%1.2 $3.92 2/15/20242,370,000 shares $8.51 million +25.4%20.1%1.6 $3.59 1/31/20241,890,000 shares $7.39 million +13.2%17.2%1.4 $3.91 1/15/20241,670,000 shares $5.86 million +208.6%15.2%1.5 $3.51 12/31/2023541,100 shares $1.50 million -9.8%4.9%0.6 $2.77 12/15/2023599,900 shares $1.59 million -11.4%5.5%3.2 $2.65 11/30/2023676,700 shares $1.67 million -15.4%6.7%3.9 $2.47 11/15/2023800,100 shares $1.58 million -7.2%6.9%1.1 $1.98 10/31/2023861,800 shares $2.09 million +3.2%9.2%1.3 $2.42 10/15/2023835,300 shares $2.16 million +25.8%8.9%1.3 $2.59 9/30/2023664,100 shares $1.75 million +37.7%7.1%1 $2.64 9/15/2023482,200 shares $1.07 million +238.4%5.2%0.8 $2.21 8/31/2023142,500 shares $252.23 thousand -1.8%1.6%0.2 $1.77 8/15/2023145,100 shares $248.12 thousand -9.3%1.6%5.7 $1.71 7/31/2023159,900 shares $311.81 thousand +15.0%1.7%4.8 $1.95 7/15/2023139,100 shares $255.94 thousand +8.9%1.5%3.7 $1.84 6/30/2023127,700 shares $249.02 thousand +18.5%1.4%3.3 $1.95 6/15/2023107,800 shares $220.99 thousand +29.4%1.2%2.7 $2.05 5/31/202383,300 shares $129.95 thousand +2.7%0.9%2.2 $1.56 5/15/202381,100 shares $111.92 thousand -7.4%0.9%1.4 $1.38 4/30/202387,600 shares $134.90 thousand +25.5%1.0%1.4 $1.54 4/15/202369,800 shares $97.72 thousand +47.3%0.8%1.2 $1.40 3/31/202347,400 shares $67.78 thousand +4.2%0.5%0.8 $1.43 3/15/202345,500 shares $69.16 thousand +237.0%0.5%0.7 $1.52 2/28/202313,500 shares $21.06 thousand -49.6%0.2%0.2 $1.56 2/15/202326,800 shares $44.66 thousand +8.1%0.3%0.5 $1.67 1/31/202324,800 shares $37.45 thousand -40.0%0.3%0.5 $1.51 1/15/202341,300 shares $70.42 thousand +50.7%0.5%0.7 $1.71 12/30/202227,400 shares $46.85 thousand +144.6%0.3%0.5 $1.71 12/15/202211,200 shares $15.34 thousand -9.7%0.1%0.2 $1.37 11/30/202212,400 shares $23.31 thousand +53.1%0.1%0.3 $1.88 11/15/20228,100 shares $15.31 thousand -16.5%0.1%0.2 $1.89 10/31/20229,700 shares $19.59 thousand +61.7%0.1%0.3 $2.02 10/15/20226,000 shares $12.54 thousand -1.6%0.1%0.2 $2.09 9/30/20226,100 shares $20.50 thousand -28.2%0.1%0.2 $3.36 9/15/20228,500 shares $40.46 thousand +6.3%0.2%0.4 $4.76 8/31/20228,000 shares $43.87 thousand -64.8%0.1%0.3 $5.48 8/15/202222,700 shares $141.88 thousand +59.9%0.4%0.9 $6.25 7/31/202214,200 shares $55.66 thousand +647.4%0.3%0.6 $3.92 7/15/20221,900 shares $8.17 thousand +111.1%N/A0.1 $4.30 6/30/20229,200 shares $3.72 thousand -55.3%0.2%0.1 $0.40 6/15/202220,600 shares $7.70 thousand -61.5%0.4%0.1 $0.37 5/31/202253,500 shares $21.94 thousand +2.9%N/A0.3 $0.41 5/15/202252,000 shares $19.76 thousand +112.2%N/A0.3 $0.38 4/30/202224,500 shares $13.11 thousand -55.7%N/A0.1 $0.54 4/15/202255,300 shares $38.08 thousand -74.2%N/A0.3 $0.69 3/31/2022214,700 shares $147.67 thousand +70.1%N/A1.1 $0.69 3/15/2022126,200 shares $59.44 thousand +10.8%N/A0.5 $0.47 2/28/2022113,900 shares $58.15 thousand -43.1%N/A0.4 $0.51 2/15/2022200,100 shares $110.46 thousand -14.4%N/A0.6 $0.55 1/31/2022233,800 shares $140.28 thousand +283.9%N/A0.7 $0.60 1/15/202260,900 shares $42.56 thousand +138.8%N/A0.2 $0.70 12/31/202125,500 shares $16.93 thousand -74.6%N/A0.1 $0.66 12/15/2021100,500 shares $68.05 thousand -32.7%N/A0.3 $0.68 11/30/2021149,300 shares $103.17 thousand +112.1%N/A0.4 $0.69 11/15/202170,400 shares $59.37 thousand -27.9%N/A0.2 $0.84 10/29/202197,700 shares $84.22 thousand -38.4%N/A0.2 $0.86 10/15/2021158,700 shares $145.54 thousand -85.2%N/A0.3 $0.92 9/30/20211,070,000 shares $989.75 thousand +2.9%N/A1.4 $0.93 9/15/20211,040,000 shares $1.02 million -4.6%N/A1.2 $0.98 8/31/20211,090,000 shares $1.11 million -16.2%N/A1.1 $1.02 8/13/20211,300,000 shares $1.13 million -13.3%N/A1.3 $0.87 7/30/20211,500,000 shares $1.64 million -5.7%3.2%1.8 $1.09 7/15/20211,590,000 shares $1.67 million +40.7%3.4%2.1 $1.05 6/30/20211,130,000 shares $1.34 million -26.1%2.4%1.6 $1.19 6/15/20211,530,000 shares $2.00 million -12.1%3.2%2.6 $1.31 5/28/20211,740,000 shares $2.85 million +4.8%3.7%2.5 $1.64 5/14/20211,660,000 shares $2.08 million -11.7%N/A1.9 $1.25 4/30/20211,880,000 shares $2.91 million +2.2%N/A1.4 $1.55 4/15/20211,840,000 shares $2.74 million -13.2%N/A1.1 $1.49 3/31/20212,120,000 shares $3.26 million -1.4%N/A1.1 $1.54 3/15/20212,150,000 shares $4.19 million -9.3%N/A0.9 $1.95 2/26/20212,370,000 shares $4.67 million +2.6%N/A0.9 $1.97 2/12/20212,310,000 shares $5.73 million +4.1%N/A0.8 $2.48 1/29/20212,220,000 shares $3.95 million -1.3%N/A0.9 $1.78 1/15/20212,250,000 shares $4.61 million -11.1%N/A1.1 $2.05 12/31/20202,530,000 shares $5.44 million -4.2%N/A1.4 $2.15 12/15/20202,640,000 shares $5.46 million +161.4%N/A1.7 $2.07 11/30/20201,010,000 shares $1.24 million -3.8%N/A1.1 $1.23 11/15/20201,050,000 shares $1.19 million -2.8%N/A3.9 $1.13 10/30/20201,080,000 shares $1.29 million +4.9%N/A2.8 $1.19 10/15/20201,030,000 shares $1.30 million -1.0%N/A1.6 $1.26 9/30/20201,040,000 shares $1.29 million +1.0%N/A1.4 $1.24 9/15/20201,030,000 shares $1.28 million -8.0%N/A1.2 $1.24 CLRB Short Interest - Frequently Asked Questions What is Cellectar Biosciences' current short interest? Short interest is the volume of Cellectar Biosciences shares that have been sold short but have not yet been closed out or covered. As of August 15th, traders have sold 94,400 shares of CLRB short. 3.19% of Cellectar Biosciences' shares are currently sold short. Learn More on Cellectar Biosciences' current short interest. What is a good short interest percentage for Cellectar Biosciences? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 3.19% of Cellectar Biosciences' floating shares are currently sold short. Is Cellectar Biosciences' short interest increasing or decreasing? Cellectar Biosciences saw a decrease in short interest in the month of August. As of August 15th, there was short interest totaling 94,400 shares, a decrease of 34.5% from the previous total of 144,100 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Cellectar Biosciences' float size? Cellectar Biosciences currently has issued a total of 3,190,000 shares. Some of Cellectar Biosciences' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Cellectar Biosciences currently has a public float of 2,960,000 shares. How does Cellectar Biosciences' short interest compare to its competitors? 3.19% of Cellectar Biosciences' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Cellectar Biosciences: Karyopharm Therapeutics Inc. (26.88%), Cue Biopharma, Inc. (1.25%), Werewolf Therapeutics, Inc. (2.90%), DURECT Corporation (1.58%), ImmuCell Corporation (0.23%), PDS Biotechnology Corporation (4.08%), Precision BioSciences, Inc. (12.88%), Actinium Pharmaceuticals, Inc. (3.24%), INmune Bio, Inc. (20.05%), ImageneBio, Inc. (0.43%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Lucid Group, Inc. ($8.00 billion), Spotify Technology ($5.48 billion), AppLovin Corporation ($5.11 billion), Reddit Inc. ($5.02 billion), Coinbase Global, Inc. ($3.99 billion), Charter Communications, Inc. ($3.89 billion), Live Nation Entertainment, Inc. ($3.18 billion), Seagate Technology Holdings PLC ($2.59 billion), ResMed Inc. ($2.55 billion), and Rocket Lab Corporation ($2.52 billion). View all of the most shorted stocks. What does it mean to sell short Cellectar Biosciences stock? Short selling CLRB is an investing strategy that aims to generate trading profit from Cellectar Biosciences as its price is falling. CLRB shares are trading up $0.20 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Cellectar Biosciences? A short squeeze for Cellectar Biosciences occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of CLRB, which in turn drives the price of the stock up even further. How often is Cellectar Biosciences' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including CLRB, twice per month. The most recent reporting period available is August, 15 2025. More Short Interest Resources from MarketBeat Related Companies Karyopharm Therapeutics Short Interest Cue Biopharma Short Interest Werewolf Therapeutics Short Interest DURECT Short Interest ImmuCell Short Interest PDS Biotechnology Short Interest Precision BioSciences Short Interest Actinium Pharmaceuticals Short Interest INmune Bio Short Interest ImageneBio Short Interest Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:CLRB) was last updated on 9/5/2025 by MarketBeat.com Staff From Our Partners“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredOne tiny company just cracked Google’s $19B problemFor decades, this “AI metal” was trapped in labs, too slow and expensive to ever reach mass production. The...True Market Insiders | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cellectar Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cellectar Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
